Phase I trial of gemcitabine, administered as a standard and constant dose-rate infusion, in combination with paclitaxel in patients with advanced solid tumors (LOA-2)

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 25, Issue 5, 2002, Pages 523-527

  Rinaldi, David A ^a   Lormand, Nancy A ^a   Brierre, Joseph E ^a   Cole, James L ^a   Stagg, M Patrick ^a   Fontenot, M Felicia ^a   Buller, Eric J ^a   Rainey, John M ^a  

^a Louisiana Oncology Associates   (United States)

Author keywords

Gemcitabine; Paclitaxel; Phase I

Indexed keywords

GEMCITABINE; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG EFFECT; FATIGUE; FEMALE; HUMAN; MALE; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; SOLID TUMOR; THROMBOCYTOPENIA;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; PACLITAXEL; UROLOGIC NEOPLASMS;

EID: 0036793738     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-200210000-00021     Document Type: Article

References (22)

1. Budman DR, Lichtman SM. Investigational drugs. In: Perry M, ed. The chemotherapy sourcebook. Baltimore: Williams & Wilkins, 1997:502-3.
2. Chu E, Mota AC, Fogarasi MC. Antimetabolites. In: Devita VT, Hellman S, Rosenberg SA, eds. Cancer. Principles and practice of oncology. 6th ed. Philadelphia: Lippincott Williams & Wilkins, 2001:402-4.
3. Grunewald R, Abbruzzese JL, Tarassoff P, et al. Saturation of 2′, 2′-difluorodeoxycytidine 5′-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine. Cancer Chemother Pharmacol 1991;27:258-62.
4. Abbruzzese JL, Grunewald R, Weeks FA, et al. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 1991;9:491-8.
5. Touroutoglou N, Gravel D, Raber MN, et al. Clinical results of a pharmacodynamically-based strategy for higher dosing of gemcitabine in patients with solid tumors. Ann Oncol 1998;9:1003-8.
6. Brand R, Capadano M, Tempero M. A phase I trial of weekly gemcitabine administered as a prolonged infusion in patients with pancreatic cancer and other solid tumors. Invest New Drugs 1997;15:331-41.
7. Rowinsky EK, Donehower RC. Microtubule-targeting agents. In: Perry M, ed. The chemotherapy sourcebook. Baltimore: Williams & Wilkins, 1997:400-8.
8. Rowinsky EK, Tolcher AW. Antimicrotubule agents. In: Devita VT, Hellman S, Rosenberg SA, ed. Cancer. Principles and practice of oncology. 6th ed. Philadelphia: Lippincott Williams & Wilkins, 2001:437-40.
9. Greco FA, Thomas M, Hainsworth JD. One-hour paclitaxel infusions: review of safety and efficacy. Cancer J Sci Am 1999;5:179-91.
10. Garfield DH, Dakhil SR, Whittaker TL, et al. Phase II randomized multicenter trial of two doses of gemcitabine as second-line therapy in patients with advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 1998;17:Abstract 1863.
11. Levitt ML, Fossella F, Devote RF. A randomized phase II study comparing two doses of gemcitabine in advanced or metastatic non-small cell lung cancer (NSCLC): preliminary results. Proc Am Soc Clin Oncol 1998;17:Abstract 1899. (Data updated by Michelini T, Eli Lilly and Company. Personal communication. September 2000.)
12. Kosmidis P, Mylonakis N, Fountzilas G, et al. Paclitaxel (175 mg/m2) plus carboplatin versus paclitaxel (225 mg/m2) plus carboplatin in non-small cell lung cancer: a randomized study. Semin Oncol 1997;24(4 suppl 12):S12-30-3.
13. Bonomi P, Kim K, Kusler J, et al. Cisplatin/etoposide vs paclitaxel/cisplatin/G-CSF vs paclitaxel/cisplatin in non-small-cell lung cancer. Oncology 1997;11(suppl 3):9-10.
14. The WHO handbook for reporting results of cancer treatment. Geneva, Switzerland: World Health Organization, 1979:48.
15. Einhom LH, Raghavan D, Kindler H, et al. A phase I trial of gemcitabine plus paclitaxel combination therapy in patients with refractory solid tumors. Proc Am Soc Clin Oncol 1998;17:Abstract 796.
16. Poole CJ, Cook J, Hogberg T, et al. A phase I clinical trial of gemcitabine and paclitaxel in patients with recurrent epithelial ovarian cancer [Abstract 341P]. Ann Oncol 1996;7(suppl 5):72.
17. Poole CJ, Perren T, Hogberg T, et al. Phase I study to investigate the optimal dose and schedule of gemcitabine (G) and paclitaxel (P) in combination in patients with previously treated epithelial ovarian cancer. Proc Am Soc Clin Oncol 1998;17:Abstract 1380.
18. Rothenberg ML, Sharma A, Weiss GR, et al. Phase I trial of paclitaxel and gemcitabine administered every two weeks in patients with refractory solid tumors. Ann Oncol 1998;9:733-8.
19. Lim N, Lara P, Edelman MJ, et al. Novel 21-day schedule of gemcitabine (GEM) and paclitaxel (TAX) in advanced solid tumors: final results of a phase I trial. Proc Am Soc Clin Oncol 2000;19:Abstract 915.
20. Glisson SD, Fleming D, Michelson G, et al. A phase I study of gemcitabine and paclitaxel in patients with solid malignancies. Proc Am Soc Clin Oncol 1999;18:Abstract 814.
21. Giaccone G, Smit EF, van Meerbeeck JP, et al. A phase I-II study of gemcitabine and paclitaxel in advanced non-small-cell lung cancer patients. Ann Oncol 2000;11:109-12.
22. Tempero M, Plunkett W, van Haperen VR, et al. Randomized phase II trial of dose intense gemcitabine by standard infusion vs. fixed dose rate in metastatic pancreatic adenocarcinoma. Proc Am Soc Clin Oncol 1999;18:Abstract 1048.